# Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

Study · id `cardio:ct-nct03902691` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03902691](<https://clinicaltrials.gov/study/NCT03902691>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03902691

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 372 participants.

## Technical summary

Registry record NCT03902691. Randomized; double masking; primary purpose treatment. Start 2019-05-15 (actual); primary completion 2021-02-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 372 participants (enrolled count; ClinicalTrials.gov record NCT03902691, source copy `cardio:ctgov-nct03902691-2023-03-09`, retrieved 2026-10-26)
- Started: 2019-05-15 (actual) (ClinicalTrials.gov record NCT03902691, source copy `cardio:ctgov-nct03902691-2023-03-09`, retrieved 2026-10-26)
- Primary completion: 2021-02-28 (actual) (ClinicalTrials.gov record NCT03902691, source copy `cardio:ctgov-nct03902691-2023-03-09`, retrieved 2026-10-26)
- Completion: 2022-05-30 (actual) (ClinicalTrials.gov record NCT03902691, source copy `cardio:ctgov-nct03902691-2023-03-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03902691, source copy `cardio:ctgov-nct03902691-2023-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03902691-2023-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Pegol-Sihematide
- Intervention (Drug): ESPO
- Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. (`cardio:org-jiangsu-hansoh-pharmaceutical-co-ltd`)

## Provenance

Content hash: 3f86bd24ba005810df8abad23336c37be852e7ab47c83264dad2dc625ca8b4da
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
